Publicação de Libbs Farmacêutica

I'm so happy to have my recent research highlighted in Onconews. The dynamic predictions provided by the survival predictive model offer valuable insights into the risks of treatment discontinuation using patient-reported outcomes data collected over time from clinical trial participants. #cancer #breastcancer #prediction #predictivemodeling #statistics #clinicaltrial #cedarssinai

Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship. Mitigando los eventos adversos tardíos y a largo plazo, asociados con el tratamiento del cáncer: implicaciones para la supervivencia. Nat Rev Clin Oncol 📖 DOI 👉🏻 10.1038/s41571-023-00776-9 #lungcancer #nsclc #sclc #noveltherapies #targettherapy #lcsm #ebm #precisiononcology #survivorship #adverseevents

📖 The ewimed Report 2024 is here! Download here: https://lnkd.in/e9aFEJva Our brand-new report summarizes the most important studies from 2023 on the topics of pleural effusion and ascites. Pleural effusion: The study by Porcel et al. "Efficacy and Safety of Indewelling Catheter for Malignant Pleural Effusions Related to Timing of Cancer Therapy: A Systematic Review" (2023), compares the efficacy and safety 🛡️ of implanted tunneled pleural catheters (IPC) depending on the timing 🕘 of systemic cancer therapy. Ascites: In the study by Tergast et al. "Daily Low-Volume Paracentesis and Clinical in Patients With Refractory Ascites: Retrospective chohort study" (2023) examined patients with cirrhosis and refractory ascites who were treated with devices such as Alfapump or tunneled intraperitoneal catheters. The complete summaries of the literature studies can be found in the new report! Download ➡️ free of charge: https://lnkd.in/eYpKCBiR 📧📞If you have any questions or suggestions, please contact at [email protected] #ewimed #patientsurvey #report #medicaltechnology #pleuraleffusion #ascites

Implantable port catheter tip location and complication rates... "The position of the catheter tip of totally implantable venous access devices (TIVAD) is a risk factor for postoperative complications. The study aim was to assess the early and late complications (EC and LC) associated with the position of the catheter tip in cancer patients" Hamri et al (2024).

Image-guided brachytherapy in cervical cancer has been developed to be a feasible and very efficient component of the treatment of locally advanced cervical cancer in addition to concurrent chemoradiation treatment. This technique allows effective dose coverage of the target while sparing the organs at risk through adjustment of the implants (intracavitary and interstitial needles) and multi-pararametric three-dimensional treatment planning. Emerging evidence from prospective studies shows a high rate of local control throughout all stages, with limited toxicity for each organ site. This is associated with a high rate of pelvic control and overall survival.

A meta-analysis scrutinizing thoracic endovascular aortic repair (TEVAR) for aorto-esophageal fistula due to esophageal cancer reveals a 90-day mortality rate of 40% among 140 cases. Hemorrhagic and infectious complications are noted at 17% and 20%, respectively. This data reflects TEVAR's role in emergent care, albeit with a caution for the observed complication rates. #EsophagealCancer #SurgicalData #TEVAROutcomes

📖 The ewimed Report 2024 is here! https://lnkd.in/d2gwD8cA Our brand-new report summarizes the most important studies from 2023 on the topics of pleural effusion and ascites. Pleural effusion: The study by Porcel et al. "Efficacy and Safety of Indewelling Catheter for Malignant Pleural Effusions Related to Timing of Cancer Therapy: A Systematic Review" (2023), compares the efficacy and safety 🛡️ of implanted tunneled pleural catheters (IPC) depending on the timing 🕘 of systemic cancer therapy. Ascites: In the study by Tergast et al. "Daily Low-Volume Paracentesis and Clinical in Patients With Refractory Ascites: Retrospective chohort study" (2023) examined patients with cirrhosis and refractory ascites who were treated with devices such as Alfapump or tunneled intraperitoneal catheters. The complete summaries of the literature studies can be found in the new report! Download ➡️ free of charge: https://lnkd.in/d2gwD8cA 📧📞If you have any questions or suggestions, please contact at [email protected] | Tel: +46 8-25 11 69 #ewimed #patientsurvey #report #medicaltechnology #pleuraleffusion #ascites

Nivolumab plus chemotherapy (Nivo-Chemo) is the standard treatment for advanced gastric cancer. However, real-world data on the efficacy of Nivo-Chemo are limited. In this MEDtalk, Dr. Mai Utsumi presents a study on the impact of adding nivolumab to first-line chemotherapy in patients with advanced gastric cancer. #ASCOGI24 #GastricCancer #Treatment

Nivolumab plus chemotherapy (Nivo-Chemo) is the standard treatment for advanced gastric cancer. However, real-world data on the efficacy of Nivo-Chemo are limited. In this MEDtalk, Dr. Mai Utsumi presents a study on the impact of adding nivolumab to first-line chemotherapy in patients with advanced gastric cancer. #ASCOGI24 #GastricCancer #Treatment